These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 8390421

  • 1. Report of phase II trial of concurrent chemoradiotherapy with radical thoracic irradiation (60 Gy), infusional fluorouracil, bolus cisplatin and etoposide for clinical stage IIIB and bulky IIIA non-small cell lung cancer.
    Langer CJ, Curran WJ, Keller SM, Catalano R, Fowler W, Blankstein K, Litwin S, Bagchi P, Nash S, Comis R.
    Int J Radiat Oncol Biol Phys; 1993 Jun 15; 26(3):469-78. PubMed ID: 8390421
    [Abstract] [Full Text] [Related]

  • 2. Long-term survival results for patients with locally advanced, initially unresectable non-small cell lung cancer treated with aggressive concurrent chemoradiation.
    Langer CJ, Curran WJ, Keller SM, Catalano RB, Litwin S, Blankstein KB, Haas N, Campli SN, Comis RL.
    Cancer J Sci Am; 1996 Jun 15; 2(2):99-105. PubMed ID: 9166507
    [Abstract] [Full Text] [Related]

  • 3. Phase I trial of concurrent thoracic radiation and continuous infusion cisplatin and etoposide in stage III non-small cell lung cancer.
    Kalemkerian GP, Belzer K, Wozniak AJ, Gaspar LE, Valdivieso M, Kraut MJ.
    Lung Cancer; 1999 Sep 15; 25(3):175-82. PubMed ID: 10512128
    [Abstract] [Full Text] [Related]

  • 4. Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study.
    Reboul F, Brewer Y, Vincent P, Chauvet B, Faure CF, Taulelle M.
    Int J Radiat Oncol Biol Phys; 1996 May 01; 35(2):343-50. PubMed ID: 8635942
    [Abstract] [Full Text] [Related]

  • 5. Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response.
    Pourel N, Santelmo N, Naafa N, Serre A, Hilgers W, Mineur L, Molinari N, Reboul F.
    Eur J Cardiothorac Surg; 2008 May 01; 33(5):829-36. PubMed ID: 18367406
    [Abstract] [Full Text] [Related]

  • 6. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P, Herndon J, Langer M, Kohman LJ, Elias AD, Kass FC, Eaton WL, Seagren SL, Green MR, Sugarbaker DJ.
    Cancer; 1996 Jun 01; 77(11):2393-9. PubMed ID: 8635112
    [Abstract] [Full Text] [Related]

  • 7. A pilot study of protracted low dose cisplatin and etoposide with concurrent thoracic radiotherapy in unresectable stage III nonsmall cell lung cancer.
    Blanke C, DeVore R, Shyr Y, Epstein B, Murray M, Hande K, Stewart S, Johnson D.
    Int J Radiat Oncol Biol Phys; 1997 Jan 01; 37(1):111-6. PubMed ID: 9054884
    [Abstract] [Full Text] [Related]

  • 8. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y, Ueoka H, Kiura K, Kamei H, Tabata M, Sakae K, Hiraki Y, Kawahara S, Eguchi K, Hiraki S, Harada M.
    Br J Cancer; 2000 Jan 01; 82(1):104-11. PubMed ID: 10638975
    [Abstract] [Full Text] [Related]

  • 9. A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small-cell lung cancer: a 5-year follow-up report.
    Lee JS, Komaki R, Fossella FV, Glisson BS, Hong WK, Cox JD.
    Int J Radiat Oncol Biol Phys; 1998 Oct 01; 42(3):479-86. PubMed ID: 9806504
    [Abstract] [Full Text] [Related]

  • 10. Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer.
    Rice TW, Adelstein DJ, Koka A, Tefft M, Kirby TJ, Van Kirk MA, Taylor ME, Olencki TE, Peereboom D, Budd GT.
    Ann Thorac Surg; 1995 Sep 01; 60(3):586-91; discussion 591-2. PubMed ID: 7677484
    [Abstract] [Full Text] [Related]

  • 11. Pre-operative chemoradiotherapy in non-small cell lung cancer stage III patients. Feasibility, toxicity and long-term results of a phase II study.
    Favaretto A, Paccagnella A, Tomio L, Sartori F, Cipriani A, Zuin R, Reffosco L, Calabro F, Rea F, Ghiotto C, Chiarion-Sileni V, Oniga F, Loreggian L, Fiorentino MV.
    Eur J Cancer; 1996 Nov 01; 32A(12):2064-9. PubMed ID: 9014746
    [Abstract] [Full Text] [Related]

  • 12. Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study.
    Hazuka MB, Crowley JJ, Bunn PA, O'Rourke M, Braun TJ, Livingston RB.
    J Clin Oncol; 1994 Sep 01; 12(9):1814-20. PubMed ID: 8083705
    [Abstract] [Full Text] [Related]

  • 13. Concurrent 5-fluorouracil, leucovorin, etoposide, cisplatin and radiotherapy for locally advanced non-small cell lung cancer.
    Yang CT, Chang WC, Chen LH, Leung WM, Lee CH, Liaw CC.
    Changgeng Yi Xue Za Zhi; 1997 Sep 01; 20(3):187-94. PubMed ID: 9397609
    [Abstract] [Full Text] [Related]

  • 14. A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers.
    Park J, Ahn YC, Kim H, Lee SH, Park SH, Lee KE, Lim DH, Park J, Kim K, Jung CW, Im YH, Kang WK, Lee MH, Park K.
    Lung Cancer; 2003 Nov 01; 42(2):227-35. PubMed ID: 14568691
    [Abstract] [Full Text] [Related]

  • 15. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.
    Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT, Weick JK, Lonchyna VA, Presant CA, McKenna RJ, Gandara DR.
    J Clin Oncol; 1995 Aug 01; 13(8):1880-92. PubMed ID: 7636530
    [Abstract] [Full Text] [Related]

  • 16. Results of a phase II concurrent chemoradiotherapy study using three-dimensional conformal radiotherapy with cisplatin and oral etoposide in stage III nonsmall-cell lung cancer.
    Chen LM, Ignacio L, Jacobs R, Kozloff M, Telfer M, Elahi R, Evans R, Vijayakumar S.
    Radiat Oncol Investig; 1999 Aug 01; 7(1):49-53. PubMed ID: 10030624
    [Abstract] [Full Text] [Related]

  • 17. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.
    Sonett JR, Suntharalingam M, Edelman MJ, Patel AB, Gamliel Z, Doyle A, Hausner P, Krasna M.
    Ann Thorac Surg; 2004 Oct 01; 78(4):1200-5; discussion 1206. PubMed ID: 15464470
    [Abstract] [Full Text] [Related]

  • 18. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
    Komaki R, Scott C, Lee JS, Urtasun RC, Byhardt RW, Emami B, Andras EJ, Asbell SO, Rotman M, Cox JD.
    Am J Clin Oncol; 1997 Oct 01; 20(5):435-40. PubMed ID: 9345325
    [Abstract] [Full Text] [Related]

  • 19. Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma.
    Langer CJ, Somer R, Litwin S, Feigenberg S, Movsas B, Maiale C, Sherman E, Millenson M, Nicoloau N, Huang C, Treat J.
    J Thorac Oncol; 2007 Mar 01; 2(3):203-9. PubMed ID: 17410043
    [Abstract] [Full Text] [Related]

  • 20. Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC).
    Elias AD, Skarin AT, Leong T, Mentzer S, Strauss G, Lynch T, Shulman L, Jacobs C, Abner A, Baldini EH, Frei E, Sugarbaker DJ.
    Lung Cancer; 1997 May 01; 17(1):147-61. PubMed ID: 9194034
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.